Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198

This is a phase II, multicenter, double-blinded, randomized, 2-arm trial evaluating the efficacy and safety of mFOLFIRINOX plus ramucirumab (Arm A) vs. mFOLFIRINOX plus placebo (Arm B) in 94 subjects with advanced pancreatic cancer, not amenable to curative treatment. Both arms will continue treatment until disease progression or unacceptable toxicity.

Study Overview

• Status: Active, not recruiting
• Conditions: Pancreatic Cancer
• Intervention / Treatment: Drug: mFOLFIRINOX; Drug: Ramucirumab; Other: Placebo

Detailed Description

OUTLINE: This is a multi-center study.

EXPERIMENTAL ARM A:

• Oxaliplatin 85 mg/m^2 over 2-4 hours
• Irinotecan 165 mg/m^2 over 90 minutes
• 5-FU 2,400 mg/m^2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.
• Arm A will receive ramucirumab (RAM) administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.

CONTROL ARM B :

• Oxaliplatin 85 mg/m2 over 2-4 hours
• Irinotecan 165 mg/m2 over 90 minutes
• 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.
• Arm B will receive a placebo infusion every 2 weeks. Due to the double-blinded nature of this study, the volume of placebo will be calculated as if it were RAM.

In order to demonstrate adequate organ function, all screening labs must be obtained within 7 days prior to registration:

Hematological:

• Hemoglobin ≥ 9 g/dL
• Absolute Neutrophil Count (ANC) ≥ 1,500/mm^3
• Platelet Count (PLT) ≥ 100,000/mm^3

Renal:

• Creatinine ≤ 1.5 mg/dL or Creatinine clearance^1 ≥ 40 mL/min
• Albumin ≥ 2.5 g/dL

Hepatic:

• Bilirubin ≤ 1.5 mg/dL
• Aspartate aminotransferase (AST) ≤ 3 × ULN or < 5 xULN in the setting of liver metastases
• Alanine aminotransferase (ALT) ≤ 3 × ULN or < 5 xULN in the setting of liver metastases

Coagulation:

• International Normalized Ratio (INR) (Patients receiving warfarin must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to first dose of protocol therapy) ≤1.5 and a partial thromboplastin time (PTT) (PTT/aPTT) < 1.5 x ULN

• Study Type: Interventional
• Enrollment (Actual): 84
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85259
      • Mayo Clinic-Arizona
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Emory University: Winship Cancer Institute
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Indiana University Melvin and Bren Simon Cancer Center
    • Munster, Indiana, United States, 46321
      • Community Healthcare System
  • Kentucky
    • Louisville, Kentucky, United States, 40202
      • University of Louisville, James Graham Brown Cancer Center
  • Nebraska
    • Omaha, Nebraska, United States, 68114
      • Nebraska Methodist Hospital
  • Pennsylvania
    • Gettysburg, Pennsylvania, United States, 17325
      • Gettysburg Cancer Center
    • Philadelphia, Pennsylvania, United States, 19107
      • Thomas Jefferson University Kimmel Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information. .
• Age ≥ 18 years at the time of consent.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 within 7 days prior to registration.
• Histologic or cytological diagnosis of recurrent or metastatic pancreas adenocarcinoma (PCA) who present for first line chemotherapy treatment.
• No prior first line systemic treatment (prior adjuvant or neoadjuvant treatment is permitted). Subjects whose disease has progressed after 6 months of last systemic chemotherapy or chemo-radiation in the adjuvant or neoadjuvant setting are eligible.
• Measurable disease determined using guidelines of Response Evaluation Criteria In Solid Tumors (RECIST 1.1). Baseline tumor assessment should be performed using high resolution computed tomography (CT) scans or magnetic resonance imaging (MRI).
• Urine protein < 1+ on dipstick test or routine urinalysis. If the proteinuria on these tests is ≥2+, then a 24-hour urine test must be collected and must demonstrate < 1g proteins in 24 hours to allow participation.
• Estimated life expectancy of >12 weeks, as assessed by the site investigator.
• If sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods) due to unknown risk of teratogenicity of ramucirumab

Exclusion Criteria:

• Subjects with histology other than adenocarcinoma; Examples include: neuroendocrine tumors, acinar cell cancer, sarcoma or lymphoma of the pancreas.
• Ongoing or active infection.
• Symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia. Symptomatic heart failure per New York Heart Association (NYHA) Class II-IV.
• Uncontrolled or poorly-controlled hypertension (>160 mmHg systolic or > 100 mmHg diastolic for >4 weeks) despite standard medical management.
• Acute or sub-acute intestinal obstruction.
• Interstitial pneumonia or interstitial fibrosis of the lung, which in the opinion of the site investigator could compromise the subject or the study.
• Pleural effusion or ascites that causes > grade 1 dyspnea.
• Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) with a history of hepatic encephalopathy or clinical meaningful ascites resulting from cirrhosis; clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis.
• Grade 3 or higher bleeding event ≤ 3 months prior to randomization.
• Experience of any arterial thrombotic or arterial thromboembolic events, including, but not limited to myocardial infarction, transient ischemic attack, or cerebrovascular accident, ≤ 6 months prior to randomization.
• History of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered "significant") during the 3 months prior to randomization.
• Documented and/or symptomatic or known brain or leptomeningeal metastases.
• GI perforation/fistula
• Documented and/or symptomatic or known brain or leptomeningeal metastases.
• Severely immune-compromised (other than being on steroids), including known HIV infection.
• Concurrent active malignancy other than adequately treated non-melanoma skin cancer, other noninvasive carcinoma, or in situ neoplasm. A subject with previous history of malignancy is eligible, provided that he/she has been disease free for > 3 years.
• Breast-feeding or pregnant.
• Prior autologous or allogeneic organ or tissue transplantation.
• Known allergy to any of the treatment components.
• Major surgery within 28 days prior to the first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement within 2 days prior to first dose of protocol therapy. The patient has elective or planned major surgery to be performed during the course of the clinical trial.
• Any condition that does not permit compliance with the study schedule including psychological, geographical or medical.
• Receiving medications that can effect clotting ability: warfarin, aspirin (once-daily aspirin use- maximum dose 325 mg/day is permitted), nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents. .
• Serious or non-healing wound, ulcer, or bone fracture within 28 days prior to first dose of protocol therapy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A: Experimental Arm; mFOLFIRINOX will be administered every 2 weeks, and consist of: Oxaliplatin 85 mg/m2 over 2-4 hours; Irinotecan 165 mg/m2 over 90 minutes; 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.; Arm A will receive ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.	Drug: mFOLFIRINOX; mFOLFIRINOX: Oxaliplatin 85 mg/m2 over 2-4 hours; Irinotecan 165 mg/m2 over 90 minutes; 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.; Drug: Ramucirumab; Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.; Other Names: Cyramza
Placebo Comparator: Arm B: Placebo Arm; mFOLFIRINOX will be administered every 2 weeks, and consist of: Oxaliplatin 85 mg/m2 over 2-4 hours; Irinotecan 165 mg/m2 over 90 minutes; 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.; Arm B will receive a placebo infusion every 2 weeks. Due to the double-blinded nature of this study, the volume of placebo will be calculated as if it were ramucirumab	Drug: mFOLFIRINOX; mFOLFIRINOX: Oxaliplatin 85 mg/m2 over 2-4 hours; Irinotecan 165 mg/m2 over 90 minutes; 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.; Other: Placebo; Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival (PFS)	PFS assessed using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) to compare outcomes of subjects on experimental arm vs control arm.	From time of registration to the time of documented progression or subject death (estimate 9 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Median Overall Survival (mOS)	mOS assessed using Kaplan-Meier Survival Analysis to compare outcomes of subjects on experimental arm vs control arm.	From time of registration to the time of documented progression or subject death, assessed up to 33 months
Response Rate (RR)	RR assessed using RECIST v1.1	From time of registration to the time of documented progression or subject death, assessed up to 33 months
Characterize Adverse Events (AE)	Toxicity assessed using Common Terminology Criteria for Adverse Events v4.0 (CTCAE v4.0)	From date of first dose until 30 days after the last treatment, assessed up to 33 months

Collaborators and Investigators

• Sponsor: Walid Shaib, MD
• Collaborators: Eli Lilly and Company; Hoosier Cancer Research Network
• Investigators: Principal Investigator: Walid Shaib, MD, Emory University

Publications and helpful links

Helpful Links

• Hoosier Cancer Research Network Website

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2016
• Primary Completion (Actual): December 5, 2022
• Study Completion (Anticipated): December 1, 2023

Study Registration Dates

• First Submitted: October 19, 2015
• First Submitted That Met QC Criteria: October 19, 2015
• First Posted (Estimate): October 20, 2015

Study Record Updates

• Last Update Posted (Estimate): December 9, 2022
• Last Update Submitted That Met QC Criteria: December 8, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Keywords: Ramucirumab; mFOLFIRINOX
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Endocrine System Diseases; Digestive System Neoplasms; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms; Antineoplastic Agents; Ramucirumab
• Other Study ID Numbers: HCRN GI14-198